Cantourage Group SE records highest monthly revenue in company history in
May 2024

EQS-News: Cantourage Group SE / Key word(s): Development of
Sales/Miscellaneous
Cantourage Group SE records highest monthly revenue in company history in
May 2024

14.06.2024 / 08:01 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Not for release, publication or distribution, directly or indirectly, in or
into the United States of America, Australia, Canada or Japan or any other
jurisdiction in which such release, publication or distribution would be
unlawful. The important notes at the end of this announcement must be
observed.

Cantourage Group SE records highest monthly revenue in company history in
May 2024

  * Revenue of EUR 3.5 million in May 2024 and the highest revenue in the
    company's history

  * Demand for Cantourage's products has increased significantly since the
    partial legalization of cannabis came into force

  * Production capacities significantly expanded to meet the anticipated
    further increase in demand

Berlin, June 14th, 2024 - Cantourage Group SE (hereinafter 'Cantourage,'
ISIN: DE000A3DSV01, www.cantourage.com), a leading European cannabis
production and distribution company, recorded revenue of EUR 3.5 million in
May 2024, the highest monthly revenue in the company's history to date.

The main drivers of the positive revenue trend are the noticeable increase
in the number of cannabis patients in Germany since the partial legalization
of cannabis came into force in April 2024 and the resulting significant
increase in demand for high-quality cannabis products. Cantourage had
prepared for this expected development and made a wide range of premium
products available to cannabis patients at an early stage. In addition, the
production facility in Germany was expanded in the first quarter of 2024.
Cantourage had already significantly expanded its grower portfolio in 2023
and opened an online platform for cannabis on prescription. The Telecan
platform ( www.telecan.eu) provides potential patients with a simple and
direct route to cannabis therapy.

Cantourage anticipates a continued increase in demand for high-quality
cannabis in the months to come - especially in Germany, but also in other
European countries. In order to be able to meet the further increase in
demand, Cantourage recently entered into a strategic partnership with the
Portuguese company Portocanna in addition to expanding its own production
facility. In the future, Portocanna's state-of-the-art production facility
will also serve as a processing site for the cannabis flowers of
Cantourage's more than 65 cultivation partners from 18 countries. The
partnership will increase Cantourage's overall capacity to deliver cannabis
flower to its European target markets from a maximum of eight to up to 14
tons per year. Cantourage is thus well equipped to reliably supply more and
more cannabis patients across Europe with high-quality products.

'Thanks to the Cannabis Act, which came into force on April 1, it has become
much easier to obtain a cannabis prescription in Germany. This is mainly due
to the fact that cannabis is no longer considered a narcotic. More and more
doctors in Germany are now willing to consider it as an option and
prescribing cannabis as a medicine. Cannabis now has the same status as
ibuprofen 600 - it is no longer a narcotic, but is available on
prescription. Overall, the acceptance of cannabis in the population has
increased noticeably due to partial legalization. In view of the new legal
situation, we assume that the number of cannabis users in Germany will
increase sustainably. By expanding our production capacities early enough,
we feel we are now well prepared for this development,' said Philip
Schetter, CEO of Cantourage.

About Cantourage

Cantourage is a leading European producer and distributor of cannabis
flowers and cannabis-based medicinal preparations and drugs. The
Berlin-based company was founded in 2019 by industry pioneers Norman
Ruchholtz, Dr. Florian Holzapfel and Patrick Hoffmann. With an experienced
management team and its 'Fast Track Access' platform, Cantourage enables
producers from around the world to become part of the growing European
medical cannabis market faster, easier and more cost-effectively by
processing and distributing their cannabis raw materials and extracts. In
this context, Cantourage ensures compliance with the highest European
pharmaceutical quality standards at all times. The company offers
pharmaceutical-grade products in all relevant market segments: dried flower,
extracts, dronabinol and cannabidiol. Cantourage was listed on the Frankfurt
Stock Exchange on 11 November 2022 and is listed under ticker symbol 'HIGH.'

Further information: www.cantourage.com

This announcement does not constitute a public offer or an advertisement for
a public offer to sell securities, in particular not within the meaning of
Regulation (EU) 2017/1129 (Prospectus Regulation).

Press contact at Cantourage:

Bernd Fischer

Phone +49 (0)30 4701 350 - 50

ir@cantourage.com


---------------------------------------------------------------------------

14.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Cantourage Group SE
                   Feurigstraße 54
                   10827 Berlin
                   Germany
   E-mail:         info@cantourage.com
   Internet:       https://www.cantourage.com/
   ISIN:           DE000A3DSV01
   WKN:            A3DSV0
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt (Scale), Munich, Stuttgart, Tradegate
                   Exchange
   EQS News ID:    1924705

End of News EQS News Service
---------------------------------------------------------------------------

1924705 14.06.2024 CET/CEST